Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation

摘要

Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive hematological neoplasm of mature CD4+ T lymphocytes.1'2 Patients with aggressive ATLL have an extremely poor prognosis because these neoplasms are resistant to conventional chemotherapy.2 Recently, Ishida et al. reported promising outcomes of treatment with a new agent, namely anti-CC chemokine receptor 4 (CCR4) MoAb (mogamulizumab), a next-generation humanized IgGI Ab with a defucosylated Fc region. This drug markedly enhances Ab-dependent CC (ADCC) through an increased binding affinity to the Fey receptor on effector cells in patients with ATLL relapse.3 CCR4 is a chemokine receptor expressed on helper T cells, regulatory T cells (Tregs)4 and certain types of T-cell neoplasms such as ATLL.5 Mogamulizumab has been approved in Japan for the treatment of relapsed or refractory ATLL. Phase II development is underway for ATLL and cutaneous T-cell lymphoma in the United States, and for peripheral T-cell lymphoma in the United States and Europe.